Form 8.3 - Horizon Therapeutics plc

Contacts

Contacts

Contacts

Search

May 09, 2023 10:25 AM Eastern Daylight Time

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	8^th May 2023

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	4,788,368	(2.093%)		-
(2) Derivatives (other than options)	-			-
(3) Options and agreements to purchase/sell	287,600	(0.126%)		1,283,600	(0.561%)
Total	5,075,968	(2.219%)		1,283,600	(0.561%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Ap20

1. DEALINGS (Note 4)

a. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (USD) (Note 5)
Sale	172	110.66
Purchase	500	110.47
Purchase	11,348	110.84
Purchase	13	110.55
Purchase	52	110.58
Purchase	3,925	110.85
Purchase	52	110.68
Purchase	99	110.56
Purchase	18	110.57
Purchase	4	110.40
Purchase	250	110.50
Purchase	4	110.73
Purchase	200	110.43
Purchase	71	110.59
Purchase	45	110.64
Purchase	216	110.83
Purchase	1,756	110.87
Sale	138	110.87
Purchase	302	110.90
Purchase	5,790	110.82
Purchase	18,665	110.86
Purchase	20	110.66
Purchase	9	110.60
Purchase	18	110.71
Purchase	299	110.46
Purchase	60	110.44
Purchase	26	110.72
Purchase	112	110.35
Purchase	1	110.65
Purchase	196	110.42
Purchase	1,418	110.89
Purchase	2,200	110.77
Purchase	597	110.38
Purchase	100	110.32
Purchase	356	110.39
Purchase	52	110.67
Purchase	300	110.93
Purchase	2	110.61
Purchase	5,167	110.88
Purchase	194	110.81
Purchase	203	110.92
Purchase	14	110.37
Purchase	127	110.75
Purchase	1,234	110.84
Sale	1,109	110.84
Purchase	8	110.82
Purchase	21	110.91
Purchase	225	110.84
Sale	72	110.90
Sale	9	110.98
Sale	27	110.91
Sale	72	111.01
Sale	3,314	110.47
Purchase	1,880	110.84
Sale	6,127	110.84
Sale	12,117	110.55
Sale	3,122	110.54
Sale	3,569	110.58
Purchase	1,365	110.85
Sale	2,020	110.85
Sale	100	110.29
Sale	500	110.80
Sale	17,136	110.56
Sale	3,364	110.57
Sale	50,883	110.50
Sale	1,429	110.73
Purchase	4	111.08
Sale	100	111.08
Sale	1,147	110.52
Sale	856	110.59
Sale	200	110.64
Purchase	2,004	110.83
Sale	5,083	110.83
Purchase	200	110.99
Sale	300	110.99
Purchase	101	110.95
Sale	2,702	110.95
Purchase	184	111.12
Sale	100	111.12
Purchase	1,426	111.09
Sale	5	111.09
Sale	1,203	110.87
Purchase	272	110.97
Sale	432	110.97
Sale	962	110.90
Purchase	202	110.96
Sale	210	110.96
Purchase	302	110.82
Sale	2,110	110.82
Purchase	558	111.00
Sale	9,500	111.00
Sale	3,328	110.86
Sale	21,444	110.66
Sale	400	110.60
Sale	371	110.71
Sale	600	110.46
Sale	10	110.72
Sale	133	110.65
Sale	600	110.62
Sale	300	110.48
Sale	374	110.42
Sale	130	110.63
Sale	1,010	110.89
Sale	944	110.94
Purchase	215	110.98
Sale	400	110.98
Sale	7,058	110.53
Sale	750	110.51
Sale	21	110.91
Sale	114	110.30
Sale	100	110.39
Purchase	153	111.14
Purchase	314	111.11
Sale	2,916	110.69
Sale	800	110.76
Sale	75	111.50
Sale	200	111.01
Sale	200	110.93
Sale	2,048	110.61
Sale	400	110.88
Purchase	1,088	110.81
Sale	965	110.81
Sale	6,881	110.49
Sale	253	110.92
Purchase	22	110.79
Sale	400	110.79
Sale	908	110.70
Sale	4,600	110.75
Sale	100	111.07
Purchase	202	111.06
Purchase	478	111.05
Purchase	194	111.02
Sale	233	111.02

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

c. Options transactions in respect of existing relevant securities

i. Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

ii. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	9^th May 2023
Contact name	Sirina Kumar
Telephone number	+44 203 192 8741
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit (USD)	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Put Option	Purchased	1,100	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	11,500	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	262,400	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	35,400	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	2,900	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	300	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	300	90.00	American	1/19/2024
IE00BQPVQZ61	Call Option	Purchased	1,200	110.00	American	8/18/2023
IE00BQPVQZ61	Call Option	Written	201,200	115.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Written	221,000	80.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	255,000	100.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,600	105.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	10,900	105.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	100,000	115.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	46,600	85.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	155,000	100.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	300	110.00	American	6/16/2023
IE00BQPVQZ61	Put Option	Purchased	200,000	100.00	American	8/18/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	95.00	American	6/16/2023
IE00BQPVQZ61	Call Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Put Option	Written	300	110.00	American	7/21/2023
IE00BQPVQZ61	Call Option	Written	400	100.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	101.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	102.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	103.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	104.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	105.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	106.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	107.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	108.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	109.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	110.00	American	5/12/2023
IE00BQPVQZ61	Call Option	Written	400	111.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	600	100.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	800	101.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	700	102.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	700	103.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	104.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	105.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	106.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	107.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	108.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	109.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	110.00	American	5/12/2023
IE00BQPVQZ61	Put Option	Written	1,000	111.00	American	5/12/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Category Code: RET

Sequence Number: 1093207

Time of Receipt (offset from UTC): 20230509T131030+0100

Millennium Partners, L.P.

Class of relevant security:

Number

Number

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell